Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy?

Melanoma Research

Volumn 9, Issue 2, 1999, Pages 181-188

  Mouawad, R ^a   Khayat, D ^a   Merle, S ^a   Antoine, E C ^a   Gil Delgado, M ^a   Soubrane, C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Endogenous interleukin 6; Functional interleukin 6 receptor; Intracellular cytokines; Metastatic malignant melanoma

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CYTOKINE RELEASE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR OCCUPANCY;

EID: 0032808970     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199904000-00011     Document Type: Article

References (38)

1. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin-6. Immunol Today 1990; 11: 443-449.
2. Evan TK, Wanagat J, Ershler WB. Molecular and cellular biology of interleukin-6 and its receptor. Front Biosci 1996; 1: 340-357.
3. Sehgal PB, Wang L, Rayanade R, Pan H, Margulies L. Interleukin-6. NY Acad Sci 1995; 762: 1-14.
4. Zhang XG, Klein B, Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989; 74: 11-13.
5. Shih I-M, Herlyn M. Role of growth factors and their receptors in the development and progression of melanoma cells. J Invest Dermatol 1993; 100: 196s-203s.
6. Lee JD, Sievers TM, Skotzko M, Chandler CF, et al. Interleukin-6 production by human melanoma cell lines. Lymphokine Cytokine Res 1992; 11: 161-166.
7. Kerbel RS. Expression of milti-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. Am J Pathol 1992; 141: 519-524.
8. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 1993; 120: 1281-1288.
9. Suematsu S, Hibi M, Sugita T, et al. Interleukin 6 (IL-6) and its receptor (IL-6R) in myeloma/plasmacytoma. Curr Top Microbiol Immunol 1990; 166: 13-22.
10. Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 1994; 56: 853-857.
11. Yamasaki K, Taga T, Hirata Y, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 1988; 241: 825-828.
12. Hirata Y, Taga T, Hibi M, Nakano N, Hirano T, Kishimoto TJ. Characterization of IL-6 receptor expression by monoclonal and polydonal antibodies. Immunology 1989; 143: 2900-2906.
13. Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989; 58: 573-581.
14. Taga T, Kishimoto T. Cytokine receptors and signal transduction. FASER J 1992; 6: 3387-3396.
15. Mouawad R, Benhammouda A, Rixe O, et al. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res 1996; 2: 1405-1409.
16. Khayat D, Borel C, Tourani JM, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993; 11: 2173-2180.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47(1): 207-214.
18. Sander B, Andersson J, Andersson U. Assessment of cytokincs by immunofluorescence and the paraformal-dehyde-saponin procedure. Immunol Rev 1991; 119: 65-93
19. Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1985; 303: 745-747.
20. Herlyn M, Malkowicz SB. Regulatory pathways in tumor growth and invasion. Lab Invest 1991; 65: 262-271.
21. Armstrong C, Murray N, Kennedy M, et al. Melanoma-derived interleukin-6 inhibits in vivo melanoma growth. J Invest Dermatol 1994; 102: 278-284.
22. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997; 57: 141-146.
23. Hibi M, Nakajima K, Hirano T. IL-6 cytokine family and signal transduction, a model of the cytokine system. J Mol Med 1996; 74: 1-12.
24. Duray PH, Pulazzo J, Gown AM, Ohuchi N. Melanoma cell heterogeneity. A study of two monoclonal antibodies compared with S-100 protein in paraffin sections. Cancer 1988; 61: 2460-2468.
25. Schwechheimer K, Zhou L. HMB45: a specific marker for melanoma metastases in the central nervous system? Vircbows Arch 1995; 426: 351-353.
26. Lavabre-Bertrand T, Exbrayat C, Liautard J, et al. Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies. Br J Haematol 1995; 91: 871-877
27. Zola H, Flego L, Sheldon A. Detection of cytokine receptors by high-sensitivity immunofluorescence flow cytometry. Immunobiology 1992; 185: 350-365.
28. Wognum AW, van Gils FC, Wagemaker G. Flow cytometric detection of receptors for interleukin-6 on bone marrow and peripheral blood cells of humans and rhesus monkeys. Blood 1993; 81: 2036-2043.
29. Silvani A, Ferrari G, Paonessa G, Toniatti C, Parmiani G, Colombo MP. Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin. Cancer Res 1995; 55: 2200-2205.
30. Snyers L, Fontaine V, Content J. Modulation of interleukin-6 receptors in human cells. Ann NY Acad Sci 1989; 557: 388-393.
31. Schwabe M, Zhao J, Kung HE Differential expression and ligand-induced modulation of the human interleukin-6 receptor on interleukin-6-responsive cells. J Biol Chem 1994; 269: 7201-7209.
32. Nakajima T, Yamamoto S, Cheng M, et al. Soluble IL-6 receptor is released from receptor-bearing cell line in vitro. Jpn J Cancer Res 1992; 83: 373-378.
33. Mullberg J, Schooltink J, Stoyan T, et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 1993; 23: 473-480.
34. Rose-John S, Schooltink H, Schmitz-Van de Leur H, Mullberg J, et al. Intracellular retention of interleukin-6 abrogates signaling. J Biol Chem 1993; 268: 22084-22091.
35. Takenawa J, Kaneko Y, Fukumoto M, et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst 1991; 83: 1668-1672.
36. Prussien C, Metcalef D. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Methods 1995; 188: 117-128.
37. Okada M, Kitahara N, Kishimoto S, et al. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immnnol 1988; 141: 1543-1549.
38. Jourdan M, Guang Zhang X, Pertier M, et al. IFN-α induces autocrine production of IL-6 in myeloma cell lines. J Immunol 1991; 147: 4402-4407.